The Best Healthcare Stocks to Buy With $50 Right Now

Pfizer trades near $27 and at ~9x forward earnings (industry avg 17.8), while Novo Nordisk is around $39 at a ~10.4x forward P/E — both are described as attractively valued given pipeline depth. Pfizer's oncology and chronic weight-management programs and Novo Nordisk's GLP-1/Wegovy franchise could materially boost sales over the next 5–10 years; Exelixis (~$41) benefits from Cabometyx revenue and a positive zanzalintinib CRC readout but faces a patent cliff with generics risk in early 2030.

Analysis

Valuation dislocation in large-cap pharma is pricing in execution and payer risk more than scientific failure; that creates asymmetric outcomes if a small number of high-impact readouts (oncology label expansions, oral GLP-1 assets, or CRC combination data) land. For a company with multiple mid/late-stage oncology programs, two successful approvals with conservative peak sales assumptions ($1.5–2.5bn each) would likely boost 3‑year EPS by ~20–35% and, if sentiment normalizes, produce 50–100% total return via both earnings and multiple expansion. Conversely, incremental weakness from step-therapy, reimbursement clamps, or meaningful safety signals could compress realized net prices by 20–30% and knock 25–40% off forward EPS expectations, so catalysts are binary and timing-sensitive (next 6–36 months).

Second-order winners from a GLP-1-driven market are not just the originators but contract manufacturers and high‑quality oral/formulation innovators; capacity constraints create durable pricing power for proven CDMOs and favor companies with in‑house oral or non-injectable differentiation. For mid-cap oncology players with a single franchise due to face generic pressure around 2030, successful label expansions into high-incidence indications like metastatic CRC materially extend cash-flow runway—each new indication that reaches $500M+ peak sales can move enterprise value by a mid‑teens percentage assuming 10–15x EV/EBITDA.

The primary tail risks are regulatory/payer backlash to rapid GLP-1 uptake, disappointing large randomized outcomes (OS/COA) in adjuvant/metastatic oncology combos, and concentrated revenue bases facing patent cliffs. These risks resolve on disparate timelines: payer/regulatory shifts can compress returns in months, trial readouts act over 6–36 months, and patent cliffs create structural revenue cliffs around multi-year horizons. Active position sizing and event-specific hedges will dominate alpha, not passive buy-and-hold.

Key Decisions for Investors

• NVO — 18–36 month core long (size 3–5% portfolio): accumulate on weakness into any 5–10% pullbacks tied to headline noise. Hedge with a 12‑month 15% OTM put (cost ~2–4% of notional) to cap downside at ~25% while leaving upside (target 40–80% under successful share retention and new indications).
• PFE — event-driven options spread 12–24 months (size 1–3%): buy a moderately OTM call spread (long 12–24m call / sell higher strike call) to convert binary trial/label upside into defined-cost exposure; target return 2–4x premium if 1–2 material approvals read out positively, max loss = premium paid (~100%).
• EXEL — 6–18 month tactical long (size 1–2%): accumulate ahead of additional CRC/combo data and potential label filings; use a protective stop at −30% or buy a cheap 12‑month put to limit downside to that level. Upside if label expansion is granted: 30–60% given high unmet need and attractive TAM dynamics.
• Relative trade — long NVO / short LLY (equal notionals, 12–24 months, size 1–2%): if you believe GLP-1 pricing pressure and payer controls accelerate, long NVO for product/portfolio breadth and short LLY to capture near-term sentiment rotation; target asymmetric payoff of 30–50% net vs limited downside if hedged with small OTM puts on the short leg.